Phosphodiesterase type 5 (PDE5) inhibitor is a class of medication that specifically targets and blocks the enzyme phosphodiesterase type 5. This enzyme is primarily found in the smooth muscle cells of the blood vessels, including those in the penis and lungs. By inhibiting PDE5, these medications promote the accumulation of cyclic guanosine monophosphate (cGMP), a chemical responsible for relaxing the smooth muscles and increasing blood flow in these areas. In the context of erectile dysfunction (ED), PDE5 inhibitors help improve blood flow to the penis, facilitating and maintaining erections. They are also used in the treatment of pulmonary arterial hypertension (PAH) to reduce blood vessel constriction and lower blood pressure in the lungs.
The global market for Phosphodiesterase Type 5 (PDE5) Inhibitor was estimated to be worth US$ 2192.7 million in 2023 and is forecast to a readjusted size of US$ 2685.1 million by 2030 with a CAGR of 2.5% during the forecast period 2024-2030.
The key players of Phosphodiesterase Type 5 (PDE5) Inhibitor include Eli Lilly, Pfizer and Bayer, etc. The top three players hold a share over 65%. Asia-Pacific is the largest market, has a share about 34%. In terms of product type, Sildenafil is the largest segment, occupied for a share of about 72%, and for application ,and in terms of application, Retail Pharmacy has a share about 49%.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Phosphodiesterase Type 5 (PDE5) Inhibitor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyse their position in the current marketplace, and make informed business decisions regarding Phosphodiesterase Type 5 (PDE5) Inhibitor.
The Phosphodiesterase Type 5 (PDE5) Inhibitor market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Phosphodiesterase Type 5 (PDE5) Inhibitor market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Phosphodiesterase Type 5 (PDE5) Inhibitor companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
麻豆原创 Segmentation
By Company
Eli Lilly
Pfizer
Bayer
BaiYunShan General Factory
Teva Pharma
SK Chemicals
Seoul Pharma
Jiangsu Yabang
VIVUS
Fujian Cosunter
Youcare Pharmaceutical
Segment by Type
Sildenafil
Tadalafil
Avanafil
Vardenafil
Others
Segment by Application
Hospital
Retail Pharmacy
Online Pharmacies
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
Chapter 2: Revenue of Phosphodiesterase Type 5 (PDE5) Inhibitor in global and regional level.
Chapter 3: Detailed analysis of Phosphodiesterase Type 5 (PDE5) Inhibitor company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Phosphodiesterase Type 5 (PDE5) Inhibitor revenue, gross margin, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 8: Europe by Type, by Application and by country, revenue for each segment.
Chapter 9: Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Study Coverage
1.1 Phosphodiesterase Type 5 (PDE5) Inhibitor Product Introduction
1.2 麻豆原创 by Type
1.2.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor 麻豆原创 Size Growth Rate by Type (2019 VS 2023 VS 2030)
1.2.2 Sildenafil
1.2.3 Tadalafil
1.2.4 Avanafil
1.2.5 Vardenafil
1.2.6 Others
1.3 麻豆原创 by Application
1.3.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor 麻豆原创 Size Growth Rate by Application (2019 VS 2023 VS 2030)
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacies
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor 麻豆原创 Size Estimates and Forecasts
2.2 Phosphodiesterase Type 5 (PDE5) Inhibitor 麻豆原创 Size by Region: 2023 Versus 2030
2.2.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Region: 2019-2024
2.2.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Forecast by Region (2025-2030)
2.2.3 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue 麻豆原创 Share by Region (2019-2030)
3 Global Phosphodiesterase Type 5 (PDE5) Inhibitor by Company
3.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Company (2019-2024)
3.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Share by Company (2019-2024)
3.3 Competitive Landscape
3.3.1 Key Phosphodiesterase Type 5 (PDE5) Inhibitor Companies around the World: Ranking by Revenue
3.3.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor 麻豆原创 Concentration Ratio (CR5 and HHI) & (2019-2024)
3.3.3 Global Phosphodiesterase Type 5 (PDE5) Inhibitor 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.4 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Companies Headquarters & Product Type
3.4.1 Phosphodiesterase Type 5 (PDE5) Inhibitor Companies Headquarters
3.4.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Companies Product & Service
3.4.3 Date of International Companies Enter into Phosphodiesterase Type 5 (PDE5) Inhibitor 麻豆原创
3.5 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Mergers & Acquisitions, Expansion Plans
4 Company Profiles
4.1 Eli Lilly
4.1.1 Eli Lilly Company Information
4.1.2 Eli Lilly Description, Business Overview
4.1.3 Eli Lilly Phosphodiesterase Type 5 (PDE5) Inhibitor Products Offered
4.1.4 Eli Lilly Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Gross Margin (2019-2024)
4.1.5 Eli Lilly Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Product in 2023
4.1.6 Eli Lilly Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Application in 2023
4.1.7 Eli Lilly Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Geographic Area in 2023
4.1.8 Eli Lilly Recent Developments
4.2 Pfizer
4.2.1 Pfizer Company Information
4.2.2 Pfizer Description, Business Overview
4.2.3 Pfizer Phosphodiesterase Type 5 (PDE5) Inhibitor Products Offered
4.2.4 Pfizer Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Gross Margin (2019-2024)
4.2.5 Pfizer Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Product in 2023
4.2.6 Pfizer Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Application in 2023
4.2.7 Pfizer Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Geographic Area in 2023
4.2.8 Pfizer Recent Developments
4.3 Bayer
4.3.1 Bayer Company Information
4.3.2 Bayer Description, Business Overview
4.3.3 Bayer Phosphodiesterase Type 5 (PDE5) Inhibitor Products Offered
4.3.4 Bayer Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Gross Margin (2019-2024)
4.3.5 Bayer Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Product in 2023
4.3.6 Bayer Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Application in 2023
4.3.7 Bayer Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Geographic Area in 2023
4.3.8 Bayer Recent Developments
4.4 BaiYunShan General Factory
4.4.1 BaiYunShan General Factory Company Information
4.4.2 BaiYunShan General Factory Description, Business Overview
4.4.3 BaiYunShan General Factory Phosphodiesterase Type 5 (PDE5) Inhibitor Products Offered
4.4.4 BaiYunShan General Factory Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Gross Margin (2019-2024)
4.4.5 BaiYunShan General Factory Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Product in 2023
4.4.6 BaiYunShan General Factory Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Application in 2023
4.4.7 BaiYunShan General Factory Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Geographic Area in 2023
4.4.8 BaiYunShan General Factory Recent Developments
4.5 Teva Pharma
4.5.1 Teva Pharma Company Information
4.5.2 Teva Pharma Description, Business Overview
4.5.3 Teva Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Products Offered
4.5.4 Teva Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Gross Margin (2019-2024)
4.5.5 Teva Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Product in 2023
4.5.6 Teva Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Application in 2023
4.5.7 Teva Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Geographic Area in 2023
4.5.8 Teva Pharma Recent Developments
4.6 SK Chemicals
4.6.1 SK Chemicals Company Information
4.6.2 SK Chemicals Description, Business Overview
4.6.3 SK Chemicals Phosphodiesterase Type 5 (PDE5) Inhibitor Products Offered
4.6.4 SK Chemicals Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Gross Margin (2019-2024)
4.6.5 SK Chemicals Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Product in 2023
4.6.6 SK Chemicals Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Application in 2023
4.6.7 SK Chemicals Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Geographic Area in 2023
4.6.8 SK Chemicals Recent Development
4.7 Seoul Pharma
4.7.1 Seoul Pharma Company Information
4.7.2 Seoul Pharma Description, Business Overview
4.7.3 Seoul Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Products Offered
4.7.4 Seoul Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Gross Margin (2019-2024)
4.7.5 Seoul Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Product in 2023
4.7.6 Seoul Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Application in 2023
4.7.7 Seoul Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Geographic Area in 2023
4.7.8 Seoul Pharma Recent Development
4.8 Jiangsu Yabang
4.8.1 Jiangsu Yabang Company Information
4.8.2 Jiangsu Yabang Description, Business Overview
4.8.3 Jiangsu Yabang Phosphodiesterase Type 5 (PDE5) Inhibitor Products Offered
4.8.4 Jiangsu Yabang Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Gross Margin (2019-2024)
4.8.5 Jiangsu Yabang Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Product in 2023
4.8.6 Jiangsu Yabang Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Application in 2023
4.8.7 Jiangsu Yabang Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Geographic Area in 2023
4.8.8 Jiangsu Yabang Recent Development
4.9 VIVUS
4.9.1 VIVUS Company Information
4.9.2 VIVUS Description, Business Overview
4.9.3 VIVUS Phosphodiesterase Type 5 (PDE5) Inhibitor Products Offered
4.9.4 VIVUS Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Gross Margin (2019-2024)
4.9.5 VIVUS Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Product in 2023
4.9.6 VIVUS Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Application in 2023
4.9.7 VIVUS Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Geographic Area in 2023
4.9.8 VIVUS Recent Development
4.10 Fujian Cosunter
4.10.1 Fujian Cosunter Company Information
4.10.2 Fujian Cosunter Description, Business Overview
4.10.3 Fujian Cosunter Phosphodiesterase Type 5 (PDE5) Inhibitor Products Offered
4.10.4 Fujian Cosunter Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Gross Margin (2019-2024)
4.10.5 Fujian Cosunter Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Product in 2023
4.10.6 Fujian Cosunter Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Application in 2023
4.10.7 Fujian Cosunter Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Geographic Area in 2023
4.10.8 Fujian Cosunter Recent Development
4.11 Youcare Pharmaceutical
4.11.1 Youcare Pharmaceutical Company Information
4.11.2 Youcare Pharmaceutical Description, Business Overview
4.11.3 Youcare Pharmaceutical Phosphodiesterase Type 5 (PDE5) Inhibitor Products Offered
4.11.4 Youcare Pharmaceutical Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Gross Margin (2019-2024)
4.11.5 Youcare Pharmaceutical Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Product in 2023
4.11.6 Youcare Pharmaceutical Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Application in 2023
4.11.7 Youcare Pharmaceutical Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Geographic Area in 2023
4.11.8 Youcare Pharmaceutical Recent Development
5 Breakdown Data by Type
5.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Type (2019-2024)
5.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Forecast by Type (2025-2030)
5.3 Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue 麻豆原创 Share by Type (2019-2030)
6 Breakdown Data by Application
6.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Application (2019-2024)
6.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Forecast by Application (2025-2030)
6.3 Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue 麻豆原创 Share by Application (2019-2030)
7 North America
7.1 North America Phosphodiesterase Type 5 (PDE5) Inhibitor 麻豆原创 Size YoY Growth 2019-2030
7.2 North America Phosphodiesterase Type 5 (PDE5) Inhibitor 麻豆原创 Facts & Figures by Country (2019-2030)
7.3 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Type (2019-2024)
7.4 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Application (2019-2024)
8 Asia-Pacific
8.1 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor 麻豆原创 Size YoY Growth 2019-2030
8.2 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor 麻豆原创 Facts & Figures by Region (2019-2030)
8.3 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Type (2019-2024)
8.4 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Application (2019-2024)
9 Europe
9.1 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor 麻豆原创 Size YoY Growth 2019-2030
9.2 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor 麻豆原创 Facts & Figures by Country (2019-2030)
9.3 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Type (2019-2024)
9.4 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Application (2019-2024)
10 Latin America
10.1 Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor 麻豆原创 Size YoY Growth 2019-2030
10.2 Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor 麻豆原创 Facts & Figures by Country (2019-2030)
10.3 Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Type (2019-2024)
10.4 Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Application (2019-2024)
11 Middle East and Africa
11.1 Middle East and Africa Phosphodiesterase Type 5 (PDE5) Inhibitor 麻豆原创 Size YoY Growth 2019-2030
11.2 Middle East and Africa Phosphodiesterase Type 5 (PDE5) Inhibitor 麻豆原创 Facts & Figures by Country (2019-2030)
11.3 Middle East and Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Type (2019-2024)
11.4 Middle East and Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Application (2019-2024)
12 Supply Chain and Sales Channel Analysis
12.1 Phosphodiesterase Type 5 (PDE5) Inhibitor Supply Chain Analysis
12.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Key Raw Materials and Upstream Suppliers
12.3 Phosphodiesterase Type 5 (PDE5) Inhibitor Clients Analysis
12.4 Phosphodiesterase Type 5 (PDE5) Inhibitor Sales Channel and Sales Model Analysis
12.4.1 Phosphodiesterase Type 5 (PDE5) Inhibitor Distribution Channel Analysis: Indirect Sales VS Direct Sales
12.4.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Distribution Channel Analysis: Online Sales VS Offline Sales
12.4.3 Phosphodiesterase Type 5 (PDE5) Inhibitor Distributors
13 麻豆原创 Dynamics
13.1 Phosphodiesterase Type 5 (PDE5) Inhibitor Industry Trends
13.2 Phosphodiesterase Type 5 (PDE5) Inhibitor 麻豆原创 Drivers
13.3 Phosphodiesterase Type 5 (PDE5) Inhibitor 麻豆原创 Challenges
13.4 Phosphodiesterase Type 5 (PDE5) Inhibitor 麻豆原创 Restraints
14 Research Findings and Conclusion
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
Eli Lilly
Pfizer
Bayer
BaiYunShan General Factory
Teva Pharma
SK Chemicals
Seoul Pharma
Jiangsu Yabang
VIVUS
Fujian Cosunter
Youcare Pharmaceutical
听
听
*If Applicable.
